Brar Rondeep, West Robert, Witten Daniela, Raman Bhargav, Jacobs Charlotte, Ganjoo Kristen
Department of Internal Medicine, Stanford University Medical Center, Stanford, Calif., USA.
Case Rep Oncol. 2009 Dec 11;2(3):242-250. doi: 10.1159/000264637.
Angiosarcoma of the breast is a rare, malignant tumor for which little is known regarding prognostic indicators and optimal therapeutic regimens. To address this issue, we performed a retrospective analysis of breast angiosarcoma cases seen at Stanford University along with immunohistochemical analysis for markers of angiogenesis. METHODS: Breast angiosarcoma cases seen between 1980 and 2008 were examined. Viable tissue blocks were analyzed for expression of vascular endothelial growth factor and its receptors. RESULTS: A total of 16 cases were identified. Data was collected regarding epidemiology, treatment, response rates, disease-free survival, and the use of various imaging modalities. Five tissue blocks remained viable for immunohistochemical analysis. Vascular endothelial growth factor-A was positively expressed in 3 of these samples. CONCLUSION: Angiosarcoma of the breast is an aggressive malignancy with a propensity for both local recurrence and distant metastases. Angiogenesis inhibition may represent a novel therapeutic modality in this rare, vascular malignancy.
乳腺血管肉瘤是一种罕见的恶性肿瘤,关于其预后指标和最佳治疗方案知之甚少。为解决这一问题,我们对斯坦福大学收治的乳腺血管肉瘤病例进行了回顾性分析,并对血管生成标志物进行了免疫组化分析。方法:检查1980年至2008年间所见的乳腺血管肉瘤病例。对有活力的组织块进行血管内皮生长因子及其受体表达分析。结果:共确定16例。收集了有关流行病学、治疗、缓解率、无病生存期及各种成像方式使用情况的数据。5个组织块仍有活力可供免疫组化分析。其中3个样本血管内皮生长因子-A呈阳性表达。结论:乳腺血管肉瘤是一种侵袭性恶性肿瘤,有局部复发和远处转移倾向。血管生成抑制可能是这种罕见的血管恶性肿瘤的一种新治疗方式。